mAbxience’s CEO Emmanuelle Lepine highlights the company’s international expansion into highly regulated markets, new investment into its Spanish manufacturing facility, and its partnership with AstraZeneca on COVID-19 vaccine manufacturing in Argentina. As representatives from the US FDA carried out a Good Clinical Practice inspection in an adjacent office, Lepine outlined mAbxience’s business-to-business model, its pipeline selection criteria, and the development of two novel molecules.
mAbxience has a different business model than the majority of big biosimilars producers which have vast sales and marketing capabilities. We have a business-to-business (B2B) model, signing partnerships with the strongest local players instead of going for a regional or global partner, as many other companies do.
